Hussein A. Abbas, M.D., Ph.D.

Peer-Reviewed Articles

1. Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Nunez Cortes AK, Kaplan M, Acharya S, Shaim H, Xu AC, Wu M, Ensley E, Fang D, Banerjee PP, Garcia LM, Tiberti S, Lin P, Rafei H, Munir MN, Moore M, Shanley M, Mendt M, Kerbauy LN, Liu B, Biederstadt A, Gokdemir E, Ghosh, Kundu K, Reyes-Silva F, Jiang XR, Wan X, Gilbert AL, Dede M, Mohanty V, Dou J, Zhang P, Liu E, Muniz-Feliciano L, Deyter GM, Jain AK, Rodriguez-Sevilla JJ, Colla S, Garcia-Manero G, Shpall EJ, Chen K, Abbas HA, Rai K, Rezvani K, Daher M. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Sci Transl Med, 2024. e-Pub 2024. PMID: 39259809.
2. Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, bAbbas HA, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol, 2024. PMID: 39303729.
3. Chomczyk M, Gazzola L, Dash S, Firmanty P, George BS, Mohanty V, Abbas HA, Baran N. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment. Front Pharmacol, 2024. PMID: 39161899.
4. Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract, 2024. PMID: 39013130.
5. Marvin-Peek J, Sasaki K, Kontoyiannis DP, Adachi J, Ohanian M, Takahashi K, Issa GC, Kornblau S, Abbas HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series. Front. Med 11, 2024.
6. Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
7. Narayanan N, Marvin-Peek J, Abouelnaaj MK, Majid D, Wang B, Brown BD, Qiu Y, Kornblau SM, Abbas HA. Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia. J Proteome Res. e-Pub 2024. PMID: 38829961.
8. Radpour R, Simillion C, Wang B, Abbas HA, Riether C, Ochsenbein AF. IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which Promote Their Expansion. Blood, 2024. PMID: 38941612.
9. Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. e-Pub 2024. PMID: 38695144.
10. Root JL, Desai PN, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay S, Alfayez M, Matthews J, Pierce S, Reville PK, Daver N, Abbas HA. Single-Cell CD4 and CD8 T Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy. Cancer Res Commun 4(3):671-681, 2024. PMID: 38391202.
11. Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. PMID: 38418901.
12. Guo S, Mohan GS, Wang B, Li T, Daver N, Zhao Y, Reville PK, Hao D, Abbas HA. Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. J Immunother Cancer 12(2):e008318, 2024. PMID: 38418394.
13. Fan H, Wang F, Zeng A, Murison A, Tomczak K, Hao D, Jelloul FZ, Wang B, Barrodia P, Liang S, Chen K, Wang L, Zhao Z, Rai K, Jain AK, Dick J, Daver N, Futreal A, Abbas HA. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun Biol 6(1):765, 2023. e-Pub 2023. PMID: 37479893.
14. Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res. e-Pub 2023. PMID: 37163233.
15. Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2022. PMID: 35405739.
16. Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Abbas HA, Woodman SE, Nates JL, D3CODE Team Collaborators. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clin Proc 98(3):451-457, 2023. e-Pub 2022. PMID: 36868753.
17. Beird HC, Yin CC, Khoury JD, Pierce SR, Abbas HA, Zhao L, Skwarska A, Qazilbash MH, Konopleva MY, Futreal A, Pemmaraju N. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv, 2023. e-Pub 2023. PMID: 36689729.
18. Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
19. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
20. Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, Blazar BR, Radojcic V, Zeidner JF, Arruda A, Wang B, Abbas HA, Minden MD, Tasian SK, Bornhäuser M, Gojo I, Luznik L. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest 132(21), 2022. e-Pub 2022. PMID: 36099049.
21. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
22. Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. e-Pub 2022. PMID: 35201293.
23. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
24. Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med 28(6):1212-1223, 2022. e-Pub 2022. PMID: 35618837.
25. Pabon CM, Abbas HA, Konopleva M. Acute myeloid leukemia: therapeutic targeting of stem cells. Expert Opin Ther Targets 26(6):1-10, 2022. e-Pub 2022. PMID: 35634856.
26. Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. Author Correction: ?Np63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun 13(1):1717, 2022. e-Pub 2022. PMID: 35338160.
27. Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. ?Np63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun 13(1):614, 2022. e-Pub 2022. PMID: 35105868.
28. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
29. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):3402-3410, 2021. e-Pub 2021. PMID: 34380367.
30. Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. PMID: 34555853.
31. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
32. Abbas HA, Reville PK, Jiang X, Yang H, Reuben A, Im JS, Little L, Sinson JC, Chen K, Futreal A, Garcia-Manero G. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Front Immunol 12:659625, 2021. e-Pub 2021. PMID: 33912187.
33. Abbas HA, Wierda WG. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol 11:668162, 2021. e-Pub 2021. PMID: 34055635.
34. Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, Daver N, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Front Oncol 11:705627, 2021. e-Pub 2021. PMID: 34422660.
35. Wilson NR, Abbas HA, Kala J. Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices. Am J Med 134(3):e147-e149, 2020. e-Pub 2020. PMID: 33121958.
36. Bui NHB, Napoli M, Davis AJ, Abbas HA, Rajapakshe K, Coarfa C, Flores ER. Spatiotemporal Regulation of ?Np63 by TGFβ-Regulated miRNAs Is Essential for Cancer Metastasis. Cancer Res 80(13):2833-2847, 2020. e-Pub 2020. PMID: 32312834.
37. Davis AJ, Tsinkevich M, Rodencal J, Abbas HA, Su XH, Gi YJ, Fang B, Rajapakshe K, Coarfa C, Gunaratne PH, Koomen JM, Tsai KY, Flores ER. TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes. Cancer Res 80(12):2484-2497, 2020. e-Pub 2020. PMID: 32156775.
38. Abbas HA, Amini B, Wang WL, Ravi V. Maneuvering the Management of a Rare Case of Primary Undifferentiated Cardiac Sarcoma. Am J Case Rep 21:e918878, 2020. e-Pub 2020. PMID: 32198341.
39. Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res 26(4):892-901, 2020. e-Pub 2019. PMID: 31694833.
40. Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, de Bont ESJM, Kornblau SM. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics Clin Appl 13(4):e1800133, 2019. e-Pub 2019. PMID: 30650251.
41. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
42. Abbas HA, Han X. Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia. N Engl J Med 380(24):2360, 2019. PMID: 31189039.
43. Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. Cancer Manag Res 11:8817-8828, 2019. e-Pub 2019. PMID: 31632141.
44. Rafei RE, Abbas HA, Alameddine H, Bizri AA, Melki I, Yunis KA. Assessing the Risk of Having Small for Gestational Age Newborns Among Lebanese Underweight and Normal Pre-pregnancy Weight Women. Matern Child Health J 22(1):130-136, 2018. PMID: 28780682.
45. Abbas HA, Bui NHB, Rajapakshe K, Wong J, Gunaratne P, Tsai KY, Coarfa C, Flores ER. Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78(2):451-462, 2018. e-Pub 2017. PMID: 29180475.
46. Abiad F, Awwad J, Abbas HA, Zebian D, Ghazeeri G. Management of weight loss in obesity-associated male infertility: a spotlight on bariatric surgery. Hum Fertil (Camb) 20(4):227-235, 2017. e-Pub 2017. PMID: 28460579.
47. Ezzeddine D, Ezzeddine D, Hamadi C, Abbas HA, Nassar A, Abiad M, Ghazeeri G. Prevalence and Correlation of Hypothyroidism With Pregnancy Outcomes Among Lebanese Women. J Endocr Soc 1(5):415-422, 2017. e-Pub 2017. PMID: 29264496.
48. Su X, Napoli M, Abbas HA, Venkatanarayan A, Bui NHB, Coarfa C, Gi YJ, Kittrell F, Gunaratne PH, Medina D, Rosen JM, Behbod F, Flores ER. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene 36(17):2377-2393, 2017. e-Pub 2016. PMID: 27869165.
49. Inati A, Mansour AG, Sabbouh T, Amhez G, Hachem A, Abbas HA. Transfusion Therapy in Children With Sickle Cell Disease. J Pediatr Hematol Oncol 39(2):126-132, 2017. PMID: 27509379.
50. Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 64(1):188-196, 2017. e-Pub 2016. PMID: 27576370.
51. Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-888, 2016. PMID: 27300436.
52. Ghazeeri G, Zebian D, Nassar AH, Harajly S, Abdallah A, Hakimian S, Skaiff B, Abbas HA, Awwad J. Knowledge, attitudes and awareness regarding fertility preservation among oncologists and clinical practitioners in Lebanon. Hum Fertil (Camb) 19(2):127-33, 2016. e-Pub 2016. PMID: 27376977.
53. Inati A, El Hachem Y, Tawk S, Kassm SA, Abbas HA. Pediatric Immune Thrombocytopenia in Lebanon: Treatment and Predictors of Outcome. Pediatr Blood Cancer 63(2):375-6, 2016. e-Pub 2015. PMID: 26313008.
54. El Rafei R, Abbas HA, Charafeddine L, Nakad P, Al Bizri A, Hamod D, Yunis KA. Association of Pre-Pregnancy Body Mass Index and Gestational Weight Gain with Preterm Births and Fetal Size: an Observational Study from Lebanon. Paediatr Perinat Epidemiol 30(1):38-45, 2016. e-Pub 2015. PMID: 26469281.
55. Batley NJ, Nasreddine Z, Chami A, Zebian D, Bachir R, Abbas HA. Cynicism and other attitudes towards patients in an emergency department in a middle eastern tertiary care center. BMC Med Educ 16:36, 2016. e-Pub 2016. PMID: 26823070.
56. Ghazeeri G, Abbas HA, Skaff B, Harajly S, Awwad J. Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. J Endocrinol Invest 38(6):643-51, 2015. e-Pub 2015. PMID: 25722221.
57. Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 62(2):371-9, 2015. e-Pub 2014. PMID: 25281858.
58. Inati A, Noureldine MA, Mansour A, Abbas HA. Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed Res Int 2015:813098, 2015. e-Pub 2015. PMID: 25834825.
59. Inati A, Noun P, Kabbara N, Salloum C, Kmeid M, Sadek M, Abbas HA, Kahale M. A multicenter study on the Lebanese experience with hereditary spherocytosis. Pediatr Blood Cancer 61(10):1895-6, 2014. e-Pub 2014. PMID: 24590699.
60. Inati A, Kahale M, Perrine SP, Chui DH, Taher AT, Koussa S, Abi Nasr T, Abbas HA, Ghalie RG. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol 164(3):456-8, 2014. e-Pub 2013. PMID: 24224649.
61. Abbas HA, Yunis K. The effect of consanguinity on neonatal outcomes and health. Hum Hered 77(1-4):87-92, 2014. e-Pub 2014. PMID: 25060272.
62. Khoriaty E, Halaby R, Berro M, Sweid A, Abbas HA, Inati A. Incidence of sickle cell disease and other hemoglobin variants in 10,095 Lebanese neonates. PLoS One 9(9):e105109, 2014. e-Pub 2014. PMID: 25180595.
63. Inati A, Abbas HA, Korjian S, Daaboul Y, Harajeily M, Saab R. A case of Pitt-Hopkins syndrome with absence of hyperventilation. J Child Neurol 28(12):1698-701, 2013. e-Pub 2012. PMID: 23248353.
64. Ghazeeri G, Fakih A, Abbas HA, Harajly S, Awwad J. Anxiety, cognitive, and depressive assessment in adolescents with polycystic ovarian syndrome: a pilot study. J Pediatr Adolesc Gynecol 26(5):269-73, 2013. e-Pub 2013. PMID: 23849090.
65. Inati A, Tourjuman O, Bizri D, Dhayni R, Abbas HA, Tfaili H, Akouri G, Beydoun A. A rare case of Moyamoya syndrome in a β-thalassemia major patient. Blood Cells Mol Dis 51(3):149-50, 2013. e-Pub 2013. PMID: 23735661.
66. Pant V, Xiong S, Jackson JG, Post SM, Abbas H, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27(17):1857-67, 2013. e-Pub 2013. PMID: 23973961.
67. Abbas HA, Kahale M, Hosn MA, Inati A. A review of acute chest syndrome in pediatric sickle cell disease. Pediatr Ann 42(3):115-20, 2013. PMID: 23458871.
68. Inati A, Abbas HA, Al-Danaf J, Souaid M, Kahale M, Koussa S, Abou Nasr T, Davis L, Luo HY, Chui DH. Identification of the first mutation in a BRE motif of the β-globin gene and its inheritance with two other α-globin gene mutations in a Lebanese family. Hemoglobin 37(2):171-5, 2013. PMID: 23470150.
69. Salman M, Khoury NJ, Khalifeh I, Abbas HA, Majdalani M, Abboud M, Muwakkit S, Solh HE, Saab R. Congenital infantile fibrosarcoma: Association with bleeding diathesis. Am J Case Rep 14:481-5, 2013. e-Pub 2013. PMID: 24265847.
70. Inati A, Akouri G, Abbas HA. A rare aggravation of severe mucositis post chemotherapy in a child with acute lymphoblastic leukemia. F1000Res 2:196, 2013. e-Pub 2013. PMID: 24555093.
71. Inati A, Abbas HA, Boumitri C, Tecle N. Prevalence of glucose-6-phosphate dehydrogenase deficiency among neonates at a tertiary care centre in Lebanon. J Med Screen 19(2):103-4, 2012. e-Pub 2012. PMID: 22554801.
72. Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle 10(19):3257-62, 2011. e-Pub 2011. PMID: 21957490.
73. Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 7(5):606-17, 2010. PMID: 21040902.
74. Post SM, Pant V, Abbas H, Quintás-Cardama A. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma. Oncotarget 1(3):168-74, 2010. PMID: 21301048.

Editorials

1. Zhao L, Zhang J, Xu L, Abbas HA. Novel Cancer Immunotherapies and Antitumor Immunity. J Immunol Res, 2019.

Abstracts

1. Farhat A, Sasaki K, Short N, Cuglievan B, Loghavi S, Patel K, Tang G, Yilmaz M, Montalban-Bravo G, Abbas H, Hammond D, Pemmaraju M, Daver N, DiNardo C, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa G. Clinical Characteristics Of Rare Genetic Alterations Associated With Upregulation Of Hoxgenes In Adults With Acute Leukemia. European Hematology Association Annual Meeting 8(Issue S1):1004-1005, 2024.
2. Jen W, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Short N, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado-Valero Y, Pemmaraju N, Ferrajoli A, Reville P, Swaminathan M, Ohanian M, Abbas H, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva M, Mullin J, Pierce S, Kantarjian H, DiNardo C. Flag-Ida + Venetoclax (Ven) In Newly Diagnosed (Nd) Or Relapsed / Refractory (Rr) Aml. European Hematology Association Annual Meeting 8(Issue S1):79-80, 2024.
3. Kugler E, Desdemir E, Wang B, Bataller A, DiNardo C, Daver N, Yilmaz M, Short N, Kadia T, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas H. Mutation Patterns And Prognostic Implications In Acute Myeloid Leukemia With Chromosomal7 Deletions. European Hematology Association Annual Meeting 8(Issue S1):1006 - 1007, 2024.
4. Montalban-Bravo G, Loghavi S, Almanza E, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa G, Abbas H, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Kanagal-Shamanna R, Wang S, Wang W, Fang H, Tang G, Pierce S, Ramos CB, Medeiros J, Kantarjian H, Garcia-Manero G. Spectrum And Clinical Implications Of Extramedullary Manifestations In Chronicmyelomonocytic Leukemia. European Hematology Association Annual Meeting 8(Issue S1):1371 - 1372, 2024.
5. Kugler E, Desdemir E, Wang B, Torralba AB, DiNardo CD, Daver N, Yilmaz M, Short N, Kadia T, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation patterns and Prognostic implications in Acute Myeloid Leukemia with chromosomal 7 deletions. American Society of Clinical Oncology Annual Meeting, Journal of Clinical Oncology 42(16), 2024.
6. Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Alvarado Valero Y, Montalban-Bravo G, Maiti A, <b>Abbas HA</b> , Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment. ASH(723), 2023. e-Pub 2023.
7. Desai PN, Wang B, Reville PK, Jelloul FZ, Borges P, Senapati J, Castillo M, Gunaratne P, Pemmaraju N, Kadia TM, Ravandi F, Garcia-Manero G, Daver N, Abbas HA. Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance. ASH(64), 2023.
8. Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, Daver N, Alvarado Valero Y, Pemmaraju N, Borthakur G, Hammond DE, Chien KS, Ferrajoli A, Short NJ, Abbas HA , Jabbour E, Andreeff M, Ravandi F, Tidwell RSS, Wang X, Konopleva MY, Garcia-Manero G, Kantarjian HM, DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update. ASH(968), 2023.
9. Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Alvarado Valero Y, Montalban-Bravo G, Maiti A, Abbas HA , Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment. ASH(1480), 2023.
10. Root JL Desai PN, Reville PK, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay SG, Alfayez M, Matthews J, Pierce S Daver N Abbas HA. Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy. ASH(1584), 2023.
11. Bijender Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Shanley M, Acharya S, Mendt MC, Lin P, Biederstädt A, Rafei H, Banerjee P, Mohanty V, Shaim H, Dede M, Garcia LM, Kerbauy LN, Nunez Cortes AK Miao Q, Dou J, Reyes FS, Guo X, Kaplan M, Ang S, Jiang XR, Liu E, Bin Liu, PhD2*, Richard E. Champlin, MD2, Kantarjian H, Marin D, Chen K, Abbas HA , Shpall EJ, Kunal Rai K, Rezvani K Daher M. Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies. ASH(2088), 2023.
12. Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Vaugh N, Baran N, Deng Q, Matthews J, Gunaratne P, Antunes DA Ekmekcioglu S, Sasaki K, Garcia MB Cuglievan B, Hao D, Daver N, Green MR, Konopleva MY, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. ASH(2796), 2023.
13. Wang B, Ly C, Dasdemir E, Jelloul FZ, Desai PN, Borges P, Root JL, Tang G, Gunaratne P, Basu S, Jindal S, Chen Y, Wani KM, Lazar AJ, Sharma P, Reville PK, Abbas HA. Characterizing Inferred Functional and Phenotypical States of Newly Diagnosed Acute Myeloid Leukemia from Single Cell Transcriptomic Profiling. ASH(2938), 2023.
14. Khasawneh A, Paran FJ, Oyama R, Maiti A, Abbas HA , Wang B, Desai PN, Hayes K, Harman JR, Su X, DiNardo CD, Andreeff M, Milne TA, Konopleva MY, Tabe Y. Molecular Profiling of Response and Resistance to Venetoclax–Decitabine Therapy in Acute Myeloid Leukemia. ASH(4159), 2023.
15. Arani N, Almanza E, Bataller A, DiNardo CD, Ravandi F, Daver N, Pemmaraju N, Yilmaz M, Maiti A, Reville PK, Loghavi S, <b>Abbas HA</b> , Garcia-Manero G, Short NJ, Kantarjian HM, Kadia TM. Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens. ASH(4236), 2023.
16. Masarova L, Kantarjian HM, Pemmaraju N, Abbas HA , Bose P, Swaminathan M, Pierce S, Sasaki K, Yilmaz M, Short NJ, Daver N, Borthakur G, Garcia-Manero G, Ohanian M, Bhalla KN, DiNardo CD, Kadia TM. Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs). ASH(4264), 2023.
17. Poonam Desai, MSc, Bofei Wang, PhD, Fatima Zahra Jelloul, MD, Gheath Alatrash, PhD, DO, Natalia Baran, MD, PhD, Qing Deng, PhD, Michael R. Green, PhD, Naval Daver, MD, Marina Konopleva, MD, PhD, Andy Futreal, PhD, Dapeng Hao and Abbas HA. Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes. ASH(4119), 2022. e-Pub 2022.
18. Bofei Wang, PhD, Fatima Zahra Jelloul, MD, Pamella Borges, Poonam Desai, MSc, Guilin Tang, MD, PhD, Marina Konopleva, MD, PhD, Natalia Baran, MD, PhD, Michael R. Green, PhD, Qing Deng, PhD, Naval Daver, MD, Andy Futreal, PhD, Dapeng Hao and Abbas HA. Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients. ASH(2790), 2022. e-Pub 2022.
19. Sangeetha Venugopal, MD, MS, Sanam Loghavi, MD, Mark Routbort, MD, PhD, Fatima Zahra Jelloul, MD, Rashmi Kanagal-Shamanna, MD, Sherry A. Pierce, BSN, BA, Ghayas C. Issa, MD, Abbas HA, Koji Sasaki, MD, Koichi Takahashi, MD, PhD, Naval Daver, MD, Farhad Ravandi, MD, Hagop Kantarjian, MD and Courtney D. DiNardo, MD, MSCE. Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies. ASH(2814), 2022. e-Pub 2022.
20. Patrick K Reville, MD, MPH, Hagop Kantarjian, MD, Gautam Borthakur, MD, Musa Yilmaz, MD, Naval Daver, MD, Nicholas Short, MD, Courtney D. DiNardo, MD, MSCE, Steven M. Kornblau, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Yesid Alvarado, MD, Prithviraj Bose, MD, Elias Jabbour, MD, Kelly S. Chien, MD, Abbas HA, Lucia Masarova, MD, Sa A Wang, MD, Rebecca S. S Tidwell, MS, Michael Andreeff, MD, PhD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Farhad Ravandi, MD and Tapan M. Kadia, MD. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. ASH(709), 2022. e-Pub 2022.
21. Naval Daver, MD, Jayastu Senapati, MD, MBBS, DM, Abhishek Maiti, MBBS, Sanam Loghavi, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, MSCE, Naveen Pemmaraju, MD, Elias Jabbour, MD, Guillermo Montalban-Bravo, MD, Guilin Tang, MD, PhD, Koji Sasaki, MD, Gautam Borthakur, MD, Musa Yilmaz, MD, Joie Alvarez, BSN, Sherry A. Pierce, BSN, BA, Graciela M. Nogueras González, MPH, Jing Ning, Ghayas C. Issa, MD, Michael Andreeff, MD, PhD, Abbas HA, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD and Hagop Kantarjian, MD. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. ASH(61), 2022. e-Pub 2022.
22. Jayastu Senapati, MD, MBBS, DM, Nicholas Short, MD, Abhishek Maiti, MBBS, Abbas HA, Naval Daver, MD, Naveen Pemmaraju, MD, Sherry A. Pierce, BSN, BA, Kelly S. Chien, MD, Koji Sasaki, MD, Danielle Hammond, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Hagop Kantarjian, MD and Courtney D. DiNardo, MD, MSCE. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia. ASH(596), 2022. e-Pub 2022.
23. Walid Macaron, MD, MSc, Farhad Ravandi, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, MSCE, Ghayas C. Issa, MD, Naval Daver, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD, PhD, Keyur Patel, MD, PhD, Sanam Loghavi, MD, Marina Konopleva, MD, PhD, Musa Yilmaz, MD, Elias Jabbour, MD, Abhishek Maiti, MBBS, Abbas HA, Elizabeth J Shpall, MD, Uday R Popat, MD, Gheath Alatrash, PhD, DO, Sherry A. Pierce, BSN, BA, Hagop Kantarjian, MD and Nicholas Short, MD. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission. ASH(224), 2022. e-Pub 2022.
24. Himachandana Atluri, MD, Abhishek Maiti, MBBS, Koji Sasaki, MD, Naval Daver, MD, Yesid Alvarado, MD, Md Feroz Hossain, MD, MS, Xuemei Wang, MS, Naveen Pemmaraju, MD, Koichi Takahashi, MD, PhD, Gautam Borthakur, MD, Alessandra Ferrajoli, Nicholas Short, MD, Abbas HA, Farhad Ravandi, MD, Elias Jabbour, MD, Michael Andreeff, MD, PhD, Guillermo Garcia-Manero, MD, Hagop Kantarjian, MD, Marina Konopleva, MD, PhD and Courtney D. DiNardo, MD, MSCE. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia. ASH(2746), 2022. e-Pub 2022.
25. Fadi Haddad, MD, Georgio Medawar, Rashmi Kanagal-Shamanna, MD, Hector Alvarez, Sanam Loghavi, MD, Naval Daver, MD, Sherry A. Pierce, BSN, BA, Elias Jabbour, MD, Tapan M. Kadia, MD, Nicholas Short, MD, Courtney D. DiNardo, MD, MSCE, Gautam Borthakur, MD, Abbas HA, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop Kantarjian, MD and Musa Yilmaz, MD. Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML). ASH(1384), 2022. e-Pub 2022.
26. Abbas HA, Edward Ayoub, PhD, Hanxiao Sun, Rashmi Kanagal-Shamanna, MD, Nicholas Short, MD, Ghayas C. Issa, MD, Musa Yilmaz, MD, Sherry A. Pierce, BSN, BA, Daniel Rivera, MD, Brent Cham, Shane Wing, Ziyi Li, PhD, Danielle Hammond, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Naval Daver, MD, Tapan M. Kadia, MD, Marina Konopleva, MD, PhD, Courtney D. DiNardo, MD, MSCE and Farhad Ravandi, MD. Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment. ASH(2701), 2022. e-Pub 2022.
27. Deng Q, Green MR, Daver N, Konopleva M, Futreal A, Hao D, Abbas HA. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II. ASH(317), 2022. e-Pub 2022.
28. Kantarjian, MD2, Naszrin Arani, MD3*, Uday R Popat, MD4, Courtney D. DiNardo, MD, MSCE1, Naval Daver, MD1, Musa Yilmaz, MD5, Abbas HA, Nicholas Short, MD6, Ghayas C. Issa, MD1, Elias Jabbour, MD1, Sherry A. Pierce, BSN, BA. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III. ASH(732), 2022. e-Pub 2022.
29. Elias Jabbour, MD1, Tapan M. Kadia, MD7, Nicholas Short, MD8, Courtney D. DiNardo, MD, MSCE1, Gautam Borthakur, MD1, Abbas HA, Naveen Pemmaraju, MD1, Guillermo Garcia-Manero, MD9, Farhad Ravandi, MD1, Hagop Kantarjian, MD10 and Musa Yilmaz, MD. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I. ASH(613), 2022. e-Pub 2022.
30. Xuemei Wang, MS4*, Naveen Pemmaraju, MD2, Koichi Takahashi, MD, PhD5, Gautam Borthakur, MD2, Alessandra Ferrajoli2, Nicholas Short, MD5, Abbas HA, Farhad Ravandi, MD2, Elias Jabbour, MD2, Michael Andreeff, MD, PhD2, Guillermo Garcia-Manero, MD6, Hagop Kantarjian, MD. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II. ASH(615), 2022. e-Pub 2022.
31. Patrick K Reville, MD, MPH, Hagop Kantarjian, MD, Gautam Borthakur, MD, Musa Yilmaz, MD, Naval Daver, MD, Nicholas Short, MD, Courtney D. DiNardo, MD, MSCE, Steven M. Kornblau, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Yesid Alvarado, MD, Prithviraj Bose, MD, Elias Jabbour, MD, Kelly S. Chien, MD, Abbas HA, Lucia Masarova, MD, Sa A Wang, MD, Rebecca S. S Tidwell, MS, Michael Andreeff, MD, PhD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Farhad Ravandi, MD and Tapan M. Kadia, MD. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance. ASH(616), 2022. e-Pub 2022.
32. Naval Daver, Marina Konopleva, Abhishek Maiti, Tapan M. Kadia, Courtney D. DiNardo, Sanam Loghavi, Naveen Pemmaraju, Elias J. Jabbour, Guillermo Montalban-Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yilmaz, Joie Alvarez, Michelle Golez, Sherry A. Pierce, Graciela M. Nogueras González, Jing Ning, Abbas HA*, Farhad Ravandi, Guillermo Garcia-Manero, and Hagop Kantarjian. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood, 2021.
33. Naval G. Daver, Sreyashi Basu, Guillermo Garcia-Manero, Abbas HA, Marina Konopleva, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Mansour Alfayez, Ahmad Alotaibi, Naveen Pemmaraju, Elias J. Jabbour, Sherry A. Pierce, Mark Brandt, Koichi Takahashi, Jing Ning, Steven M. Kornblau, Koji Sasaki, Musa Yilmaz, Ghayas Issa, Nicholas Short, Jairo Matthews, Wilmer Flores, Michael Andreeff, Jorge E. Cortes, Farhad Ravandi, James P Allison, Padmanee Sharma, and Hagop M. Kantarjian, MD. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. American Society of Hematology Annual Meeting, 2020.
34. Abbas HA*, Patrick K Reville, Alexis Geppner, Caitlin R Rausch, Naveen Pemmaraju, Maro Ohanian, Koji Sasaki, Gautam Borthakur, Naval Daver, Courtney Dinardo, Carlos Bueso-Ramos, Michael Andreeff, Nicholas Short, Sherry Pierce, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia. Clinical course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma. American Society of Hematology Annual Meeting, 2020.
35. Abbas HA*, Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K Reville, Zoe Alaniz, Wei Wang, Ruiping Wang, Feng Wang, Koichi Takahashi, Jing Ning, Maomao Ding, Jairo A. Matthews, Latasha Little, Jianhua Zhang, Sreyashi Basu, Courtney D. DiNardo, Tapan M. Kadia, Farhad Ravandi, Gautam Borthakur, Marina Konopleva, Guillermo Garcia-Manero, Michael R Green, Gheath Alatrash, Padmanee Sharma, James P Allison, Steven M. Kornblau, Kunal Rai, Linghua Wang, P Andrew Futreal, and Naval Daver. Single-cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy, 2020.
36. Abbas HA, Ngoc Hoang Bao Bui,, Kimal Rajapakshe, Justin Wong, Preethi Gunaratne, Kenneth Y. Tsai, Cristian Coarfa, Elsa R. Flores. Agnostic Transcriptional Profiling of The Cancer Genome Atlas Data Identifies Distinct and Cooperative Role of TP63 Isoforms in Renal Cancer Subtypes That Drive Progression and Predict Clinical Outcomes. International Kidney Cancer Society Annual Meeting, 2019.
37. Abbas HA, Mansour Alfayez, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia, Courtney Denton Dinardo, Jairo Mathews, Wilmer Flores, Michael Andreeff, Steven Mitchell Kornblau, Marina Konopleva, Jorge E. Cortes, Sattva Swarup Neelapu, Hagop M. Kantarjian, Richard Eric Davis, Naval Guastad Daver. RNA based immune signatures may Predict Responses to PD-1 Inhibition and Azacitidine Treatment in Acute Myeloid Leukemia (AML): A subset analysis of a Phase 2 Study. European Hematology Association Annual Meeting, 2019.
38. Naval G. Daver, Guillermo Garcia-Manero, Marina Y Konopleva, Mansour Alfayez, Naveen Pemmaraju, Tapan M. Kadia, Courtney D. DiNardo, Jorge E. Cortes, Farhad Ravandi, Abbas HA, Sreyashi Basu, Elias Jabbour, Sherry A. Pierce, Zeev E. Estrov, Koichi Takahashi, Jing Ning, Steven M. Kornblau, Koji Sasaki, Lucia Masarova, Wilmer Flores , James P Allison, Padmanee Sharma, Hagop M. Kantarjian. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. American Society of Hematology Annual Meeting, 2019.
39. Abbas HA, Mansour Alfayez, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia, Courtney Denton Dinardo, Jairo Mathews, Wilmer Flores, Michael Andreeff, Steven Mitchell Kornblau, Marina Konopleva, Jorge E. Cortes, Sattva Swarup Neelapu, Hagop M. Kantarjian, Richard Eric Davis, Naval Guastad Daver. IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): a subset analysis of a phase 2 study. American Society of Clinical Oncology Annual Meeting, 2019.
40. Abbas HA*, Cristian Coarfa and Elsa Flores. Mining The Cancer Genome Atlas for TP53 Family Transcriptional Regulatory Networks. Fourth Annual Meeting for The Cancer Genome Atlas. National Institute of Health (NIH), 2015.
41. Marco Napoli, Avinashnarayan Venkatanarayan, Payal Raulji, Abbas HA, William Norton, Anil K. Sood, Gabriel Lopez-Berestein, Kenneth Y. Tsai, Cristian Coarfa, Preethi H. Gunaratne, Elsa R. Flores. Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutant tumors. America Association for Cancer Research Meeting, 2015.
42. Adlette Inati, Stephanie Farah, Dina Khammash, Mario Kahale, Abbas HA, George Azar. Ophthalmologic complications in a sickle cell disease cohort in North Lebanon. European Hematology Association Annual Meeting, 2014.
43. A. Inati, M. Kahale, S. P. Perrine, A.Taher, S. Koussa, Abbas HA, T. Abi Nader, and R. G. Ghalie. A phase 2 trial of the hemoglobin inducer HQK-1001 (2,2-dimethylbutyrate, sodium salt) in nontransfusion-dependent β-Thalassemia (study LB-04 THAL). ASH, 2013.
44. Evelyne Khoriaty, Rim Halaby, Mohamad Berro, Ahmad Sweid, Abbas HA and Adlette Inati. Neonatal screening program for inherited haemoglobin disorders in public hospitals across. 6th Europediatrics, 2013.
45. Adlette Inati, Javid Gaziev, Serge Korjian, Yazan Daaboul, Mario Kahale, Abbas HA, Katia Paciaroni, Gioia De Angelis, Ali Taher, Therese Abi Nasr Suzan Koussa, and Guido Lucarelli. A Lebanese-Italian Collaborative Initiative on Bone Marrow Transplantation in Pediatric Patients with β-Thalassemia Major. European Hematology Association Meeting, 2013.
46. Ghina Ghaziri, Ahmad Fakih, Abbas HA, Sally Harajly, Johny Awwad. Anxiety, Cognitive and Depressive Assessment in Adolescents with Polycystic Ovary Syndrome: A Pilot Study. European Society of Human Reproduction and Embryology Meeting, 2013.
47. Adlette Inati, Abbas HA, Mirna Souaid, Suzan Koussa, Ali Taher, Therese Abou Nasr, and David Chui. Identification of the First Mutation in BRE Motif of β-globin & Its Polygenic Inheritance with Two Other α-globin Mutations in Patients of the Same Family. European Hematology Association Meeting, 2012.
48. Evelyne Khoriaty, Rim Halaby, Abbas HA, Ahmad Sweid, Mohamad Berro, and Adlette Inati. Neonatal Screening for Hemoglobinopathies in Public Hospitals across Lebanon. European Hematology Association Meeting, 2012.
49. Abbas HA, Suleyman Coskun, Tiffany Sills, M. James You, Karen K. Hirschi and Guillermina Lozano. Mdm2 regulation of ROS-activated p53 is indispensable for survival of hematopoietic progenitor and stem cells. Gordon Research Conference: Stem cells and cancer, 2009.
50. Samih Y. El Ahdab, Ryan Castoro, Abbas HA, Saira Ahmed, Jaroslav Jelinek, Jean-Pierre Issa. Epigenetic profiling of apoptotic genes in leukemia and colon cancer. American Association for Cancer Research Annual Meeting, 2008.
51. Samih El Ahdab,Ryan Castoro, Abbas HA, Saira Ahmed, Jaroslav Jelinek, Jean-Pierre Issa. Methylation Profiling of Apoptotic Genes in Leukemia Cell Lines and Patients. Blood (American Society of Hematology Annual Meeting), 2007.
52. Ahmad Houri, Abbas HA, and Abbas Abdallah. The role of Natural Reserves in Awareness Raising and Biodiversity Conservation. Proceedings of the "International Conference on Environment 2006 (ICENV2006), 2006.
53. Ahmad Houri, Saadieh el-Jeblawi, Mirvat Hammoud and Abbas HA. Effect of Current Culture of Water Use on Coastal River Water Quality in Lebanon. Proceeding of the “International Conference on Water Culture and Water Environment Protection, 2005.

Book Chapters

1. Abbas HA, Saab R. Premalignancy and Cellular Senescence. In: Tumor Dormancy, Quiescence, and Senescence, Volume 2. Springer, 195-206, 2013.

Books (edited and written)

1. Abbas HA, Houri AF. In: Student's Guide to Graduate School, First. Self Publish, 2011.